Literature DB >> 28246231

Association between statin use and ischemic stroke or major hemorrhage in patients taking dabigatran for atrial fibrillation.

Sebastian Haertter1, Fenglei Huang2, Lionel Riou Franca3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28246231      PMCID： PMC5325739          DOI： 10.1503/cmaj.732623

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  7 in total

Review 1.  The incident user design in comparative effectiveness research.

Authors:  Eric S Johnson; Barbara A Bartman; Becky A Briesacher; Neil S Fleming; Tobias Gerhard; Cynthia J Kornegay; Parivash Nourjah; Brian Sauer; Glen T Schumock; Art Sedrakyan; Til Stürmer; Suzanne L West; Sebastian Schneeweiss
Journal:  Pharmacoepidemiol Drug Saf       Date:  2012-10-01       Impact factor: 2.890

Review 2.  Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors.

Authors:  David Williams; John Feely
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

3.  Association between statin use and ischemic stroke or major hemorrhage in patients taking dabigatran for atrial fibrillation.

Authors:  Tony Antoniou; Erin M Macdonald; Zhan Yao; Simon Hollands; Tara Gomes; Mina Tadrous; Muhammad M Mamdani; David N Juurlink
Journal:  CMAJ       Date:  2016-11-21       Impact factor: 8.262

4.  Assessing the comparative effectiveness of newly marketed medications: methodological challenges and implications for drug development.

Authors:  S Schneeweiss; J J Gagne; R J Glynn; M Ruhl; J A Rassen
Journal:  Clin Pharmacol Ther       Date:  2011-11-02       Impact factor: 6.875

5.  Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial.

Authors:  K-H Liesenfeld; T Lehr; C Dansirikul; P A Reilly; S J Connolly; M D Ezekowitz; S Yusuf; L Wallentin; S Haertter; A Staab
Journal:  J Thromb Haemost       Date:  2011-11       Impact factor: 5.824

Review 6.  Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate.

Authors:  Joachim Stangier
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

7.  Evaluating medication effects outside of clinical trials: new-user designs.

Authors:  Wayne A Ray
Journal:  Am J Epidemiol       Date:  2003-11-01       Impact factor: 4.897
  7 in total
  1 in total

1.  Response to "Association between statin use and ischemic stroke or major hemorrhage in patients taking dabigatran for atrial fibrillation".

Authors:  Tony Antoniou; Muhammad Mamdani; David Juurlink
Journal:  CMAJ       Date:  2017-02-27       Impact factor: 8.262
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.